{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:36:56Z","timestamp":1790786216081,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018955","name":"Leeds Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018787","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.semarthrit.2023.152259","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T02:46:12Z","timestamp":1692413172000},"page":"152259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension"],"prefix":"10.1016","volume":"63","author":[{"given":"Maria Antonietta","family":"D'Agostino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Carron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corine","family":"Gaillez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G","family":"Conaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Naredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"L\u00f3pez-Rdz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"\u0160enolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Burgos-Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Hanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Padovano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Cazenave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria S","family":"Stoenoiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Backhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebl","family":"Mouterde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punit","family":"Goyanka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Boers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.semarthrit.2023.152259_bib0001","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","article-title":"Psoriatic arthritis from a mechanistic perspective","volume":"18","author":"Schett","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152259_bib0002","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/annrheumdis-2018-213609","article-title":"Reliability of a consensus-based ultrasound definition and scoring for enthesitis in spondyloarthritis and psoriatic arthritis: An OMERACT US initiative","volume":"77","author":"Balint","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152259_bib0003","article-title":"Scoring ultrasound synovitis in rheumatoid arthritis: A EULAR-OMERACT ultrasound taskforce-part 1: definition and development of a standardised, consensus-based scoring system","volume":"3","author":"D'Agostino","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2023.152259_bib0004","first-page":"S352","article-title":"Assessment of OMERACT global power Doppler ultrasonography 44-joint scoring system and reduced joint scoring systems in rheumatoid arthritis patients treated with abatacept plus background methotrexate","volume":"64","author":"D'Agostino","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152259_bib0005","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2014-206971","article-title":"EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice","volume":"74","author":"Mandl","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152259_bib0006","first-page":"848","article-title":"The OMERACT ultrasound group: status of current activities and research directions","volume":"34","author":"Wakefield","year":"2007","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152259_bib0007","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1136\/ard.2005.051235","article-title":"Power Doppler ultrasonography and synovitis: correlating ultrasound imaging with histopathological findings and evaluating the performance of ultrasound equipments","volume":"65","author":"Koski","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152259_bib0008","first-page":"keab628","article-title":"Response to secukinumab on synovitis using power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study","author":"D'Agostino","year":"2021","journal-title":"ULTIMATE. Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152259_bib0010","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.10812","article-title":"Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: a cross-sectional study","volume":"48","author":"D'Agostino","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152259_bib0011","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/acr.22191","article-title":"Defining enthesitis in spondyloarthritis by ultrasound: results of a delphi process and of a reliability reading exercise","volume":"66","author":"Terslev","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152259_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-017-1399-5","article-title":"The association between sonographic enthesitis and radiographic damage in psoriatic arthritis","volume":"19","author":"Polachek","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152259_bib0013","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13075-018-1653-5","article-title":"Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study","volume":"20","author":"Kampylafka","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152259_bib0014","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/acr2.11097","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 FUTURE 1 study","volume":"2","author":"Mease","year":"2020","journal-title":"ACR Open Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152259_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000723","article-title":"Secukinumab in the treatment of psoriatic arthritis: Efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial","volume":"4","author":"Mease","year":"2018","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152259_bib0016","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1016\/S2665-9913(20)30036-9","article-title":"Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study","volume":"2","author":"McInnes","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"suppl 10","key":"10.1016\/j.semarthrit.2023.152259_bib0009","article-title":"Secukinumab significantly decreased joint synovitis measured by power doppler ultrasonography in biologic-na\u00efve patients with active psoriatic arthritis: primary (12-week) results from a randomized, placebo-controlled phase III study [abstract]","volume":"72","author":"D'Agostino","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"20","key":"10.1016\/j.semarthrit.2023.152259_bib0017","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World medical association declaration of helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"issue":"314","key":"10.1016\/j.semarthrit.2023.152259_bib0018","article-title":"POS0197\u2005Responsiveness of ultrasound synovitis and clinical outcomes in psoriatic arthritis treated with secukinumab: data from the ULTIMATE trial","volume":"80","author":"Boers","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152259_bib0019","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/art.38940","article-title":"Power and color Doppler ultrasound settings for inflammatory flow: impact on scoring of disease activity in patients with rheumatoid arthritis","volume":"67","author":"Torp-Pedersen","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152259_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001600","article-title":"Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study","volume":"7","author":"Mease","year":"2021","journal-title":"RMD Open"},{"issue":"11","key":"10.1016\/j.semarthrit.2023.152259_bib0021","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","article-title":"Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study","volume":"56","author":"McInnes","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152259_bib0022","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s10067-020-05450-4","article-title":"Doppler enthesitis: A potential useful outcome in the assessment of axial spondyloarthritis and psoriatic arthritis","volume":"40","author":"Molina Collada","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2023.152259_bib0023","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2021-eular.463","article-title":"POS0194\u2005Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of EXCEED","volume":"80","author":"Kaeley","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"9999","key":"10.1016\/j.semarthrit.2023.152259_bib0024","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.semarthrit.2023.152259_bib0025","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223001014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223001014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:11:01Z","timestamp":1758733861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017223001014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":25,"alternative-id":["S0049017223001014"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152259","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152259","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152259"}}